- Home
- ITIC vs DSGN Comparison
ITIC vs DSGN Comparison
Compare ITIC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- DSGN
- Stock Information
- Founded
- ITIC 1972
- DSGN 2017
- Country
- ITIC United States
- DSGN United States
- Employees
- ITIC N/A
- DSGN N/A
- Industry
- ITIC Specialty Insurers
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ITIC Finance
- DSGN Health Care
- Exchange
- ITIC Nasdaq
- DSGN Nasdaq
- Market Cap
- ITIC 404.7M
- DSGN 348.2M
- IPO Year
- ITIC N/A
- DSGN 2021
- Fundamental
- Price
- ITIC $228.05
- DSGN $5.06
- Analyst Decision
- ITIC
- DSGN Hold
- Analyst Count
- ITIC 0
- DSGN 3
- Target Price
- ITIC N/A
- DSGN $7.00
- AVG Volume (30 Days)
- ITIC 12.7K
- DSGN 220.6K
- Earning Date
- ITIC 02-11-2025
- DSGN 03-18-2025
- Dividend Yield
- ITIC 6.95%
- DSGN N/A
- EPS Growth
- ITIC 22.45
- DSGN N/A
- EPS
- ITIC 15.10
- DSGN N/A
- Revenue
- ITIC $241,018,000.00
- DSGN N/A
- Revenue This Year
- ITIC N/A
- DSGN N/A
- Revenue Next Year
- ITIC N/A
- DSGN N/A
- P/E Ratio
- ITIC $15.10
- DSGN N/A
- Revenue Growth
- ITIC 1.93
- DSGN N/A
- 52 Week Low
- ITIC $146.41
- DSGN $2.25
- 52 Week High
- ITIC $290.40
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ITIC 39.00
- DSGN 44.20
- Support Level
- ITIC $225.24
- DSGN $3.71
- Resistance Level
- ITIC $231.29
- DSGN $6.81
- Average True Range (ATR)
- ITIC 6.06
- DSGN 0.49
- MACD
- ITIC 0.26
- DSGN -0.14
- Stochastic Oscillator
- ITIC 58.01
- DSGN 43.55
About ITIC Investors Title Company
Investors Title Co operates primarily in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment primarily issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.